Phoenix Bio

研究発表

研究発表

Chimeric mouse with humanized liver, an emerging tool for the drug development「創薬ツールとしてのヒト肝細胞キメラマウス」

    Shimada, T.
    Nihon Yakurigaku Zasshi. 2023;158(6):483-489. doi: 10.1254/fpj.23038.

    Hepatocyte-targeted siTAZ therapy lowers liver fibrosis in NASH diet-fed chimeric mice with hepatocyte-humanized livers

      Wang, X. Moore, M. P. Shi, H. Miyata, Y. Donnelly, S. K. Radiloff, D. R. Tabas, I.
      Mol Ther Methods Clin Dev. 2023 Nov 23;31:101165. doi: 10.1016/j.omtm.2023.101165. eCollection 2023 Dec 14.

      Quantitative prediction of CYP3A-mediated drug-drug interactions by correctly estimating fraction metabolized using human liver chimeric mice

        Miyake, T. Mochizuki, T. Nakagawa, T. Nakamura, M. Emoto, C. Komiyama, N. Hirabayashi, M. Tsuruta, S. Shimojo, T. Terao, K. Tachibana, T.
        Br J Pharmacol. 2023 Oct 23. doi: 10.1111/bph.16270.

        PXBマウス関連の学会発表(NASH病態モデル動物)のご紹介:メディフォード株式会社

        以下学会にて、メディフォード株式会社様 (旧:株式会社LSIM安全科学研究所様) がPXBマウス関連の
        研究発表を予定していますのでご案内申し上げます。


        第97回日本薬理学会年会(神戸国際会議場・神戸国際展示場2号館)
        開催日:2023年12月14日~12月16日


        【詳細】
        <一般演題・ポスター>
        演題番号:1-B-P057
        演題:「ヒト肝細胞キメラマウス(PXB-Mouse®)を用いた非アルコール性脂肪肝炎(NASH)モデルの開発と

        ピオグリタゾンの薬効評価」

        演者:SHUKUROV IBROHIMJON 様(メディフォード株式会社)
        日時:12月14日(木) 13:50~14:30

        Efficient gene transduction in pigs and macaques with the engineered AAV vector AAV.GT5 for hemophilia B gene therapy

          Kashiwakura, Y. Endo, K. Ugajin, A. Kikuchi, T. Hishikawa, S. Nakamura, H. Katakai, Y. Baatartsogt, N. Hiramoto, T. Hayakawa, M. Kamoshita, N. Yamazaki, S. Kume, A. Mori, H. Sata, N. Sakata, Y. Muramatsu, S. I. Ohmori, T.
          Mol Ther Methods Clin Dev. 2023 Aug 22;30:502-514. doi: 10.1016/j.omtm.2023.08.016.

          2023/09/21

          日本薬物動態学会第38回年会での口演発表のご案内

          2023年9月26日(火)からグランシップ(静岡県コンベンションアーツセンター)で開催されます、
          日本薬物動態学会第38回年会/第23回シトクロムP450国際会議国際合同大会にて、
          弊社より口演発表及び企業展示がございますのでご案内申し上げます。

           

          また、9月25日(月)に同会場で開催の日本薬物動態学会 第16回ショートコースにて、
          ランチョンセミナーを開催致しますので、重ねてご案内申し上げます。

          Evaluation of RNAi Therapeutics VIR-2218 and ALN-HBV for Chronic Hepatitis B: Results From Randomized Clinical Trials

            Gane, E. Lim, Y. S. Kim, J. B. Jadhav, V. Shen, L. Bakardjiev, A. I. Huang, S. A. Cathcart, A. L. Lempp, F. A. Janas, M. M. Cloutier, D. J. Kaittanis, C. Sepp-Lorenzino, L, Hinkle, G. Taubel, J. Haslett, P. Milstein, S. Anglero-Rodriguez, Y. I. Hebner, C. M. Pang, P. S. Yuen, M. F.
            J Hepatol. 2023 Jun 6:S0168-8278(23)00352-5. doi: 10.1016/j.jhep.2023.05.023.

            Persistent hepatic IFN system activation in HBV-HDV infection determines viral replication dynamics and therapeutic response

              Chida, T. Ishida, Y. Morioka, S. Sugahara, G. Han, C. Lam, B. Yamasaki, C. Sugahara, R. Li, M. Tanaka, Y. Liang, T. J. Tateno, C. Saito, T.
              JCI Insight. 2023 May 8;8(9):e162404. doi: 10.1172/jci.insight.162404.

              Characterization of a Novel Capsid Assembly Modulator for the Treatment of Chronic Hepatitis B Virus Infection

                Burdette, D. Hyrina, A. Song, Z. Beran, R. K. Cheung, T. Gilmore, S. Kobayashi, T. Li, L. Liu, Y. Niedziela-Majka, A. Medley, J. Mehra, U. Morganelli, P. Novikov, N. Niu, C. Tam, D. Tang, J. Wang, J. Yue, Q. Fletcher, S. P. Holdorf, M. M. Delaney, W. E. th Feierbach, B. Lazerwith, S.
                Antimicrob Agents Chemother. 2023 Jan 24;67(1):e0134822. doi: 10.1128/aac.01348-22.

                Novel AAV-mediated genome editing therapy improves health and survival in a mouse model of methylmalonic acidemia

                  Zhang, S. Bastille, A. Gordo, S. Ramesh, N. Vora, J. McCarthy, E.Zhang, X. Frank, D. Ko, C. W. Wu, C. Walsh, N. Amarwani, S. Liao, J. Xiong, Q. Drouin, L. Hebben, M. Chiang, K. Chau, B. N.
                  PLoS One. 2022 Sep 20;17(9):e0274774. doi: 10.1371/journal.pone.0274774.

                  Novel approach for verification of a human PBPK modeling strategy using chimeric mice in the health risk assessment of epyrifenacil

                    Hirasawa, K. Abe, J. Nagahori, H. Kitamoto, S
                    Toxicol Appl Pharmacol. 2023 Apr 15;465:116439. doi: 10.1016/j.taap.2023.116439. Epub 2023 Feb 27.

                    A Novel Anti-HBV Agent, E-CFCP, restores Hepatitis B virus (HBV)-induced Senescence-associated Cellular Markers Perturbation in Human Hepatocytes

                      Takamatsu, Y. Hayashi, S. Kumamoto, H. Imoto, S. Tanaka, Y. Mitsuya, H. Higashi-Kuwata, N.
                      Virus Res. 2023 Mar 23;329:199094. doi: 10.1016/j.virusres.2023.199094.

                      HBV with precore and basal core promoter mutations exhibits a high replication phenotype and causes ER stress-mediated cell death in humanized liver chimeric mice

                        Uchida, T. Imamura, M. Hayes, C. N. Suehiro, Y. Teraoka, Y. Ohya, K. Aikata, H. Abe-Chayama, H. Ishida, Y. Tateno, C. Hara, Y. Hino, K. Okamoto, T. Matsuura, Y. Aizaki, H. Wake, K. Kohara, M. Liang, T. J. Oka, S. Chayama, K.
                        Hepatology. 2023 Mar 13. doi: 10.1097/HEP.0000000000000335.

                        Identification of SARS-CoV-2 M(pro) inhibitors containing P1′ 4-fluorobenzothiazole moiety highly active against SARS-CoV-2

                          Higashi-Kuwata, N. Tsuji, K. Hayashi, H. Bulut, H. Kiso, M. Imai, M. Ogata-Aoki, H. .Ishii, T. Kobayakawa, T. Nakano, K. Takamune, N. Kishimoto, N. Hattori, S. I. Das, D. Uemura, Y. Shimizu, Y. Aoki, M. Hasegawa, K. Suzuki, S. Nishiyama, A. Saruwatari, J. Shimizu, Y. Sukenaga, Y. Takamatsu, Y. Tsuchiya, K. Maeda, K. Yoshimura, K. Iida, S. Ozono, S. Suzuki, T. Okamura, T. Misumi, S. Kawaoka, Y. Tamamura, H. Mitsuya, H.
                          Nat Commun. 2023 Feb 25;14(1):1076. doi: 10.1038/s41467-023-36729-0.

                          Patient-derived monoclonal antibody neutralizes HCV infection in vitro and vivo without generating escape mutants

                            Yokokawa, H. Shinohara, M. Teraoka, Y. Imamura, M. Nakamura, N. Watanabe, N. Date, T. Aizaki, H. Iwamura, T. Narumi, H. Chayama, K. Wakita, T.
                            PLoS One. 2022 Sep 22;17(9):e0274283. doi: 10.1371/journal.pone.0274283. eCollection 2022.

                            Prediction of the human pharmacokinetics of epyrifenacil and its major metabolite, S-3100-CA, by a physiologically based pharmacokinetic modeling using chimeric mice with humanized liver

                              Hirasawa, K. Abe, J. Nagahori, H. Kitamoto, S.
                              Toxicol Appl Pharmacol. 2022 Mar 15;439:115912. doi: 10.1016/j.taap.2022.115912.

                              Discovery of a first-in-class orally available HBV cccDNA inhibitor

                                Wang, L. Zhu, Q. Zhang, J. D. Zhang, Y. Ni, X. Xiang, K. Jiang, J. Li, B. Yu, Y. Hu, H. Zhang, M. Wu, W. Zeng, J. Yan, Z. Dai, J. Sun, K. Zhang, X. Chen, D. Feng, S. Sach Peltason, L. Young, J. A. T. Gao, L.
                                J Hepatol. 2022 Dec 29:S0168-8278(22)03466-3. doi: 10.1016/j.jhep.2022.12.014.

                                Characterization and Prevention of Hypovitaminosis C in Chimeric Mice with Humanized Livers

                                  Touchette, Erin K. Bates, Maria C. Johnson, Mitch C. O’Brien, Tracy C. Melton, Roger J. Long, Kelly R. Kakuni, Masakazu, Baginski, Matthew, Radiloff, Daniel R. Sagartz, John E.
                                  Comparative Medicine 2022, 72(6): 355-363.

                                  Characterization of a KDM5 small molecule inhibitor with antiviral activity against hepatitis B virus

                                    Gilmore, S. A. Tam, D. Cheung, T. L. Snyder, C. Farand, J. Dick, R.Matles, M. Feng, J. Y.Ramirez, R.Li, L. Yu, H. Xu, Y.Barnes, D. Czerwieniec, G. Brendza, K. M. Appleby, T. C. Birkus, G. Willkom, M. Kobayashi, T. Paoli, E. Labelle, M. Boesen, T.Tay, C. H. Delaney, W. E. thNotte, G. T. Schmitz, U. Feierbach, B.
                                    PLoS One. 2022 Dec 7;17(12):e0271145. doi: 10.1371/journal.pone.0271145. eCollection 2022.

                                    Physiologically based pharmacokinetic modeling for quantitative prediction of exposure to a human disproportionate metabolite of the selective Na(v)1.7 inhibitor DS-1971a, a mixed substrate of cytochrome P450 and aldehyde oxidase, using chimeric mice with humanized liver

                                      Asano, D. Nakamura, K. Nishiya, Y. Shiozawa, H. Takakusa, H. Shibayama, T. Inoue, S. I. Shinozuka, T. Hamada, T. Yahara, C. Watanabe, N. Yoshinari, K.
                                      Drug Metab Dispos. 2023 Jan;51(1):67-80. doi: 10.1124/dmd.122.001000. Epub 2022 Oct 23.